Recent Achievements : REUTERS - U.S. health regulators approved Indian drugmaker Dr Reddy's Laboratories' application to market generic version of AstraZeneca Plc's.
Dr Reddys Laboratories has been an outperformer and we are assuming that previous decline was a correction and it has just come out of a small trading range. As pharmaceuticals are outperforming after a correction DR Reddy is a buy on dips stock.
Buy DR Reddy in the range of 1631 to 1642 for a medium to long term target of 1685, 1715, 1815 with a stop loss of 1590.
sure ..ill wait for this ..
ReplyDeleteDR Reddy is not moving. Please close this call and exit all your positions cost to cost.
ReplyDeleteAlthough we exited DR Reddy cost to cost but as expected all 1685 and 1715 targets done
ReplyDeleteYesterday DRReddy touched 1810 high...we deadly missed this stock...
ReplyDelete